We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CoVepiT

News List

First patient dosed with multi-variant second-generation COVID-19 vaccine europeanpharmaceuticalreview
May 28, 2021
The first-in-human trial of OSE Immunotherapeutics’ multi-variant, second-generation COVID-19 vaccine has enrolled and dosed its first participant.
OSE Immunotherapeutics Receives Funding for Second Generation COVID-19 Vaccine americanpharmaceuticalreview
January 07, 2021
OSE Immunotherapeutics announces the Company has obtained funding of €5.2 million under the PSPC-COVID call for projects, operated on behalf of the French government by Bpifrance as part of the Programme d’investissements d’avenir (PIA) and led by the ...
OSE Provides Update on COVID-19 Vaccine americanpharmaceuticalreview
November 16, 2020
OSE Immunotherapeutics has announced successful completion of its human ex vivo study with CoVepiT, a prophylactic vaccine based on optimized epitopes selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2, the virus that ..
OSE’s Covid-19 vaccine shows promise in preclinical studies pharmaceutical-technology
August 18, 2020
OSE Immunotherapeutics has reported positive data from preclinical and human ex-vivo studies of its Covid-19 vaccine candidate, CoVepiT.